GlobeNewswire: SPR Therapeutics, Inc. Contains the last 10 of 46 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T06:26:49ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/01/2822064/0/en/SPR-Therapeutics-Announces-85-Million-in-Additional-Funding-to-Advance-Rapid-Commercial-Expansion-of-the-SPRINT-PNS-System.html?f=22&fvtc=4&fvtv=31142SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System2024-02-01T14:00:00Z<![CDATA[CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic pain, today announced that it has secured $85 million in financing including $25 million in Series D-1 insider equity and a $60 million debt facility. The equity financing was led by Revelation Partners, SPR’s lead investor of the Series D equity financing, and incumbent investors, RC Capital and Mutual Capital Partners. The debt facility is provided by SLR Capital Partners and Armentum Partners served as the Company’s financial advisor.]]>https://www.globenewswire.com/news-release/2024/01/16/2809931/0/en/SPR-Therapeutics-Announces-Extensive-Set-of-Abstracts-to-be-Shared-at-North-American-Neuromodulation-Society-NANS-Annual-Meeting-2024.html?f=22&fvtc=4&fvtv=31142SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 20242024-01-16T14:00:00Z<![CDATA[- Data presented features nerve targets throughout the body, highlighting the versatility of the SPRINT® PNS System - - Data presented features nerve targets throughout the body, highlighting the versatility of the SPRINT® PNS System -]]>https://www.globenewswire.com/news-release/2023/12/12/2795009/0/en/SPR-Therapeutics-Announces-Completion-of-Enrollment-in-the-RESET-Clinical-Trial-of-the-SPRINT-PNS-System-for-Low-Back-Pain.html?f=22&fvtc=4&fvtv=31142SPR Therapeutics Announces Completion of Enrollment in the RESET Clinical Trial of the SPRINT® PNS System for Low Back Pain2023-12-12T16:48:45Z<![CDATA[- RESET is the largest prospective, multicenter randomized controlled trial of SPRINT PNS conducted to date - - RESET is the largest prospective, multicenter randomized controlled trial of SPRINT PNS conducted to date -]]>https://www.globenewswire.com/news-release/2023/11/13/2779129/0/en/New-SPR-Therapeutics-Data-Presented-at-ASRA-Pain-Medicine-Meeting-2023.html?f=22&fvtc=4&fvtv=31142 New SPR Therapeutics Data Presented at ASRA Pain Medicine Meeting 20232023-11-13T14:05:00Z<![CDATA[Three Posters Accepted Including a President’s Choice Award for New Data from a Randomized Controlled Trial on Total Knee Replacement Postoperative Pain Three Posters Accepted Including a President’s Choice Award for New Data from a Randomized Controlled Trial on Total Knee Replacement Postoperative Pain]]>https://www.globenewswire.com/news-release/2023/08/22/2729707/0/en/SPR-Therapeutics-Announces-20-000th-Patient-Implant-of-SPRINT-PNS-System.html?f=22&fvtc=4&fvtv=31142SPR Therapeutics Announces 20,000th Patient Implant of SPRINT® PNS System2023-08-22T14:00:00Z<![CDATA[Commercial expansion and real-world evidence results in doubling of total implants in just over a year Commercial expansion and real-world evidence results in doubling of total implants in just over a year]]>https://www.globenewswire.com/news-release/2023/06/25/2694009/0/en/SPR-Therapeutics-Named-a-Top-Workplace-for-Second-Consecutive-Year.html?f=22&fvtc=4&fvtv=31142SPR Therapeutics Named a Top Workplace for Second Consecutive Year2023-06-25T12:00:00Z<![CDATA[- Company maintains focus on employee engagement and success while experiencing dynamic growth -]]>https://www.globenewswire.com/news-release/2023/05/17/2671194/0/en/Real-World-Data-from-Over-6-100-Patients-Corroborates-Significant-Pain-Reduction-from-Prior-Prospective-Studies-for-Patients-Treated-with-SPRINT-PNS.html?f=22&fvtc=4&fvtv=31142Real-World Data from Over 6,100 Patients Corroborates Significant Pain Reduction from Prior Prospective Studies for Patients Treated with SPRINT® PNS2023-05-17T14:16:51Z<![CDATA[CLEVELAND, May 17, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics announced the publication of a comprehensive real-world retrospective data analysis of over 6,100 patients demonstrating significant pain relief following 60-day percutaneous peripheral nerve stimulation (PNS) treatment with the SPRINT® PNS System in the journal Pain Physician.]]>https://www.globenewswire.com/news-release/2023/05/04/2661801/0/en/SelectHealth-Initiates-Peripheral-Nerve-Stimulation-PNS-Coverage-to-Support-Patient-Need-for-Effective-Non-opioid-Pain-Treatment.html?f=22&fvtc=4&fvtv=31142SelectHealth Initiates Peripheral Nerve Stimulation (PNS) Coverage to Support Patient Need for Effective Non-opioid Pain Treatment2023-05-04T15:07:58Z<![CDATA[CLEVELAND, May 04, 2023 (GLOBE NEWSWIRE) -- SelectHealth, a non-profit health plan with over one million members, has demonstrated leadership amid the opioid crisis by creating one of the first coverage policies supporting the use of Peripheral Nerve Stimulation (PNS). SPR Therapeutics is pleased to see this occur at a time when PNS, such as that delivered by the SPRINT® PNS System, is fast becoming a leading and mainstream non-opioid treatment for chronic pain. With more than thirty peer-reviewed publications supporting the use of SPRINT PNS across a wide range of pain conditions, SelectHealth is taking steps to assure access for their members to this FDA-cleared treatment as well as other PNS treatments.]]>https://www.globenewswire.com/news-release/2023/04/25/2654094/0/en/New-SPRINT-extensa-XT-System-with-Bimodal-PNS-Offers-Synergistic-Treatment-of-Pain.html?f=22&fvtc=4&fvtv=31142New SPRINT extensa XT™ System with Bimodal PNS™ Offers Synergistic Treatment of Pain2023-04-25T14:00:00Z<![CDATA[CLEVELAND, Ohio, April 25, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic pain, announced the introduction of the SPRINT extensa XT System with bimodal peripheral nerve stimulation (PNS), designed to deliver a comprehensive approach to the alleviation of pain by treating dual nerve targets with synergistic stimulation modalities.]]>https://www.globenewswire.com/news-release/2023/03/16/2628606/0/en/SPR-Therapeutics-14-Month-Data-from-Multicenter-Low-Back-Pain-Trial-Demonstrates-Significant-Durable-Impacts-on-Pain-Intensity-Disability-and-Pain-Interference.html?f=22&fvtc=4&fvtv=31142SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference2023-03-16T12:00:00Z<![CDATA[CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients suffering from acute or chronic pain, announced the peer-reviewed publication of final patient-reported outcomes from the largest prospective, multicenter trial completed to date of temporary peripheral nerve stimulation (PNS) for chronic low back pain.]]>